Johnson & Johnson (JNJ) : Money flow in the Johnson & Johnson (JNJ) stock was negative (4.44 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $63.51 million, compared to $67.95 million on downticks. The total uptick to downtick ratio was 0.93, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($4.95 million), indicating selling on the strength. The transaction value during uptick in block trades was $5.7 million. Downtick transaction value in block trades amounted to $10.65 million, indicating persistent selling. The uptick to downtick ratio was 0.54. Johnson & Johnson (JNJ) traded $0.03 higher at $119.25 gaining 0.03% over the previous days close.
Shares of Johnson & Johnson appreciated by 0.4% during the last five trading days but lost 0.44% on a 4-week basis. Johnson & Johnson is up 0.72% in the last 3-month period. Year-to-Date the stock performance stands at 18.69%.
Johnson & Johnson (JNJ) has an average broker rating of 2.11, which is interpreted as a Buy, as rated by 18 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Johnson & Johnson (NYSE:JNJ): The stock opened at $119.05 and touched an intraday high of $119.52 on Wednesday. During the day, the stock corrected to an intraday low of $118.81, however, the bulls stepped in and pushed the price higher to close in the green at $119.39 with a gain of 0.14% for the day. The total traded volume for the day was 5,076,091. The stock had closed at $119.22 in the previous trading session.
Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.